A third of myeloma patients in remission more than 5 years after cilta-cel treatment
Long-term follow-up from the CARTITUDE-1 study showed that 33% of heavily pretreated patients with multiple myeloma (MM) were in remission for 5 or
Cellular Therapy
Multiple Myeloma
Ambassador Program
News
Society Updates
SOHO regional meeting in Brazil delivers again
SOHO President Phillip Scheinberg, MD, PhD, head of the Division of Hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, wrote
18-IMCL
Vitamin D supplementation does not improve DLBCL outcomes
A study found that low baseline vitamin D is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL); however, supplementation
News
Society Updates
SOHO President Dr. Scheinberg drops hint on 2025 surprise
Phil Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, shares his first impressions of
EHA 2025
Study supports frontline use of imetelstat for low-risk MDS patients ineligible for ESAs
A post-hoc analysis of pooled data from the IMerge trial found that patients with low-risk myelodysplastic syndromes (MDS) who were ineligible for erythropoiesis-stimulating
18-IMCL
News
ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma
Researchers presented 4-year follow-up data from the phase 2 ELARA study, showing that response to tisagenlecleucel continues to deepen in patients with follicular
2025 ASCO
Video Interviews
What do the real-world data show on luspatercept in LR-MDS?
In this video interview with Idoroenyi Amanam, MD, an assistant professor in City of Hope’s Division of Leukemia in the Department of Hematology
18-IMCL
News
GOLSEEK-1 phase 3 study of golcadomide for untreated LBCL
Golcadomide, an investigational first-in-class oral CELMoD, is being assessed in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients with high-risk
EHA 2025
B-ALL patients refractory to brexu-cel face poor survival outcomes
Relapse after treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) is associated with limited survival outcomes, “underscoring a need
EHA 2025
Pediatric-inspired Ph– ALL protocol reduces toxicity without improving survival
Researchers introduced a pediatric-inspired treatment protocol at their institution for patients with Philadelphia-negative (Ph–) acute lymphoblastic leukemia (ALL) and found that overall survival